1. Report Introduction 2. Chronic Heart Failure 2.1. Overview 2.2. History 2.3. Chronic Heart Failure Symptoms 2.4. Causes 2.5.Pathophysiology 2.6. Chronic Heart Failure Diagnosis 2.6.1. Diagnostic Guidelines 3. Chronic Heart Failure Current Treatment Patterns 3.1. Chronic Heart Failure Treatment Guidelines 4. Chronic Heart Failure - DelveInsight's Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Chronic Heart Failure companies collaborations, Licensing, Acquisition -Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Chronic Heart Failure Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis 4.1.2.3. Chronic Heart Failure Acquisition Analysis 5. Therapeutic Assessment 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development 5.1.2. Assessment by Product Type (Mono / Combination) 5.1.2.1. Assessment by Stage and Product Type 5.1.3. Assessment by Route of Administration 5.1.3.1. Assessment by Stage and Route of Administration 5.1.4. Assessment by Molecule Type 5.1.4.1. Assessment by Stage and Molecule Type 5.1.5. Assessment by MOA 5.1.5.1. Assessment by Stage and MOA 5.1.6. Assessment by Target 5.1.6.1. Assessment by Stage and Target 6. Chronic Heart Failure Late Stage Products (Phase-III) 7. Chronic Heart Failure Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Chronic Heart Failure Discontinued Products 13. Chronic Heart Failure Product Profiles 13.1. Drug Name: Company 13.1.1. Product Description 13.1.1.1. Product Overview 13.1.1.2. Mechanism of action 13.1.2. Research and Development 13.1.2.1. Clinical Studies 13.1.3. Product Development Activities 13.1.3.1. Collaboration 13.1.3.2. Agreements 13.1.3.3. Acquisition 13.1.3.4. Patent Detail 13.1.4. Tabulated Product Summary 13.1.4.1. General Description Table Detailed information in the report? 14. Chronic Heart Failure Key Companies 15. Chronic Heart Failure Key Products 16. Dormant and Discontinued Products 16.1. Dormant Products 16.1.1. Reasons for being dormant 16.2. Discontinued Products 16.2.1. Reasons for the discontinuation 17. Chronic Heart Failure Unmet Needs 18. Chronic Heart Failure Future Perspectives 19. Chronic Heart Failure Analyst Review 20. Appendix 21. Report Methodology 21.1. Secondary Research 21.2. Expert Panel Validation

Table 1: Chronic Heart Failure Diagnostic Guidelines Table 2: Chronic Heart Failure Treatment Guidelines Table 3: Assessment Summary Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis Table 5: Chronic Heart Failure Acquisition Analysis Table 6: Assessment by Phase of Development Table 7: Assessment by Product Type (Mono / Combination) Table 8: Assessment by Stage and Product Type Table 9: Assessment by Route of Administration Table 10: Assessment by Stage and Route of Administration Table 11: Assessment by Molecule Type Table 12: Assessment by Stage and Molecule Type Table 13: Assessment by MOA Table 14: Assessment by Stage and MOA Table 15: Assessment by Target Table 16: Assessment by Stage and Target Table 17: Chronic Heart Failure Late Stage Products (Phase-III) Table 18: Chronic Heart Failure Mid Stage Products (Phase-II) Table 19: Chronic Heart Failure Early Stage Products (Phase-I) Table 20: Pre-clinical and Discovery Stage Products Table 21: Inactive Products Table 22: Dormant Products Table 23: Discontinued Products Figure 1: Disease Overview Figure 2: History Figure 3: Symptoms Figure 4: Causes Figure 5: Pathophysiology Figure 6: Diagnostic Guidelines Figure 7: Treatment Guidelines Figure 8: Chronic Heart Failure companies collaborations, Licensing, Acquisition -Deal Value Trends Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis Figure 10: Chronic Heart Failure Acquisition Analysis Figure 11: Assessment by Phase of Development Figure 12: Assessment by Product Type (Mono / Combination) Figure 13: Assessment by Stage and Product Type Figure 14: Assessment by Route of Administration Figure 15: Assessment by Stage and Route of Administration Figure 16: Assessment by Molecule Type Figure 17: Assessment by Stage and Molecule Type Figure 18: Assessment by MOA Figure 19: Assessment by Stage and MOA Figure 20: Late Stage Products (Phase-III) Figure 21: Mid Stage Products (Phase-II) Figure 22: Early Stage Products (Phase-I) Figure 23: Pre-clinical and Discovery Stage Products Figure 24: Inactive Products Figure 25: Dormant Products Figure 26: Discontinued Products Figure 27: Unmet Needs